Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck.
Int J Biol Sci
; 16(14): 2506-2517, 2020.
Article
em En
| MEDLINE
| ID: mdl-32792853
ABSTRACT
Immunotherapies such as immune checkpoint blockade benefit only a portion of patients with head and neck squamous cell carcinoma. The multidisciplinary field of nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer immunotherapy and to turn non-responders into responders. Various methods have been developed to deliver therapeutic agents that can overcome bio-barriers, improve therapeutic delivery into the tumor and lymphoid tissues and reduce adverse effects in normal tissues. Additional modification strategies also have been employed to improve targeting and boost cytotoxic T cell-based immune responses. Here, we review the state-of-the-art use of nanotechnologies in the laboratory, in advanced preclinical phases as well as those running through clinical trials assessing their advantages and challenges.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Nanomedicina
/
Neoplasias de Cabeça e Pescoço
/
Imunoterapia
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article